<SEC-DOCUMENT>0001193125-15-374555.txt : 20151112
<SEC-HEADER>0001193125-15-374555.hdr.sgml : 20151112
<ACCEPTANCE-DATETIME>20151112064534
ACCESSION NUMBER:		0001193125-15-374555
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151112
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151112
DATE AS OF CHANGE:		20151112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HISTOGENICS CORP
		CENTRAL INDEX KEY:			0001372299
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36751
		FILM NUMBER:		151221327

	BUSINESS ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-457-7900

	MAIL ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d28858d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Current Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event Reported): November&nbsp;12, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>HISTOGENICS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36751</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3522315</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>830 Winter Street, 3rd Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Waltham, Massachusetts 02451 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(781) 547-7900 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;12, 2015, Histogenics Corporation (the
&#147;Company&#148; or &#147;Histogenics&#148;) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended September&nbsp;30, 2015. The press release is furnished as
Exhibit&nbsp;99.1 to this Current Report on Form 8-K and is incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various statements to be made during the conference call
are &#147;forward-looking statements&#148; under the securities laws. Words such as, but not limited to, &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;design,&#148;
&#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;target,&#148; &#147;likely,&#148; &#147;should,&#148; &#147;will,&#148; and
&#147;would,&#148; or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and
uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Important factors that could cause actual results to differ materially from those reflected in the Company&#146;s forward-looking
statements include, among others: the timing and success of Histogenics&#146; NeoCart<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Phase 3 clinical trial, including, without limitation, possible delays in enrolling the NeoCart<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Phase 3 clinical trial; the ability to obtain and maintain regulatory approval of NeoCart<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or any product candidates, and the labeling for
any approved products; the scope, progress, expansion, and costs of developing and commercializing Histogenics&#146; product candidates; the ability to obtain and maintain regulatory approval regarding the comparability of critical NeoCart<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> raw materials following our technology transfer and manufacturing location transition; the size and growth of the potential markets for Histogenics&#146; product candidates and the ability to
serve those markets; Histogenics&#146; expectations regarding its expenses and revenue; the sufficiency of Histogenics&#146; cash resources and needs for additional financing; Histogenics&#146; ability to attract or retain key personnel; the
technologies on which Histogenics&#146; channel partnering agreement with Intrexon Corporation is based are currently in preclinical and clinical stages of development; Histogenics will incur additional expenses in connection with its exclusive
channel collaboration agreement with Intrexon Corporation and other factors that are described in the &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of
Histogenics&#146; Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014 and Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2015, which are on file with the SEC and available on the SEC&#146;s website at
<U>www.sec.gov</U>. Additional factors may also be set forth in those sections of Histogenics&#146; quarterly report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2015, to be filed with the SEC in the fourth quarter of 2015. In addition
to the risks described above and in Histogenics&#146; Annual Report on Form&nbsp;10-K and Quarterly Reports on Form&nbsp;10-Q, Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and other filings with the SEC, other unknown or
unpredictable factors also could affect Histogenics&#146; results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the actual results or developments anticipated by
Histogenics will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Histogenics. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and
estimates will be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All written and verbal forward-looking statements attributable to Histogenics or any person acting on its behalf are
expressly qualified in their entirety by the cautionary statements contained or referred to herein. Histogenics cautions investors not to rely too heavily on the forward-looking statements Histogenics makes or that are made on its behalf. The
information conveyed on the conference call will be provided only as of the date of the call, and Histogenics undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements made during
the call after the date thereof, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in Item&nbsp;2.02 of this Current
Report on Form&nbsp;8-K and the Exhibit attached hereto shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Exhibits</I></B> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Histogenics Corporation dated November 12, 2015.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>HISTOGENICS CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;12, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam Gridley</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Adam Gridley</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Histogenics Corporation dated November 12, 2015.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d28858dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g28858ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL AND OPERATING RESULTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Completion of Enrollment of NeoCart&reg; Phase 3 Trial Now Expected in Second Quarter of 2017 - </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALTHAM, Mass., November&nbsp;12, 2015 /GLOBE NEWSWIRE/</B> &#150; Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company
focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended September&nbsp;30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;With our new team fully in-place, we are working aggressively to enroll our NeoCart Phase 3 clinical trial, complete the technical transfer activities
for our manufacturing operations, continue to support our collaboration with Intrexon, and explore opportunities to enhance and expand our pipeline,&#148; stated Adam Gridley, President and Chief Executive Officer of Histogenics. &#147;We are
disappointed that the trial will take longer to enroll than initially expected, but are encouraged by what we see and hear from our investigators regarding their patients that receive NeoCart in the trial and we will be carefully managing our
operations to achieve our enrollment goals.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third Quarter 2015 and Recent Highlights </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Histogenics has enrolled a total of 103 patients in its NeoCart Phase 3 trial and now expects to complete enrollment by the end of the second quarter of 2017. Histogenics completed in the second and third quarters
several enrollment optimization initiatives, which included a change in patient recruiting efforts as well as changes to the site initiation process. These efforts are beginning to positively impact enrollment. In addition, Histogenics continues to
change the mix of sites with a goal of increasing the rate of enrollment. In the third quarter, Histogenics closed several more low-performing clinical sites than originally anticipated and now has 32 sites in this trial. Histogenics&#146; new
clinical leadership has already identified additional investigative sites to bring the total to the 40 permitted sites in the first quarter of 2016. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Histogenics recently completed the last performance qualification manufacturing run for collagen, which is a key raw material needed for the manufacture of NeoCart.&nbsp;In the coming months, Histogenics intends to
complete the manufacturing transition of the remaining raw materials, including the scaffold component and surgical adhesive for NeoCart, pending approval by the United States Food and Drug Administration. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Histogenics and Intrexon Corporation (Intrexon), Histogenics&#146; collaboration partner for potential next generation products, are pursuing an induced pluripotent stem cells&nbsp;(iPSC) approach, and continue to make
excellent progress on a multi-step process development plan for an iPSC chondrocyte program. The partners have multiple scientific pathways ongoing with plans for a pilot manufacturing run in the first quarter of 2016 using Intrexon&#146;s cell line
in the NeoCart cell and tissue engineering manufacturing process.</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In October 2015, Histogenics received a United States Patent regarding a method of preparing an implant for cartilage repair. Histogenics believes this patent further enhances the protection around Histogenics&#146;
NeoCart proprietary collagen scaffolds. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In September and October 2015, Histogenics hosted its first Scientific Advisory Board meetings focused on its tissue engineering and biomaterials capabilities, and on its future stem cell and regenerative medicine
platform opportunities. Feedback from the members of the Scientific Advisory Board was universally positive regarding the quality of the data generated to date from the laboratory work as well as the clinical trials, and Histogenics looks forward to
exploring further opportunities to expand its future pipeline. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g28858ex99_1logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Histogenics has initiated discussions around various business development opportunities including collaborations around the commercial rights to NeoCart outside of the United States, including recent discussions with
our licensing partner in Japan with regards to an accelerated regulatory process in that market. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;</B>We have now identified and
consented almost half of the patients in the NeoCart Phase 3 clinical trial and believe that we are beginning to see the early results from the changes we made to our clinical strategy in the second and third quarters of 2015,&#148; stated
Dr.&nbsp;Gloria Matthews, Histogenics&#146; Chief Medical Officer. &#147;We believe the positive momentum that we have recently seen is a result of our new approach that focuses on replacing certain existing sites with higher-enrolling sites;
focused, local patient recruiting done in conjunction with the investigators; and a practice management mindset in close cooperation with study coordinators,&#148; concluded Dr.&nbsp;Matthews. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Results for the Third Quarter of 2015 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the
third quarter of 2015, Histogenics reported a net loss attributable to common stockholders of $(8.1) million, or $(0.61) per share, compared to $(12.0) million, or $(19.38) per share, in the third quarter of 2014. The third quarter of 2014 included
a $3.0&nbsp;million gain related to fair value adjustments to certain liabilities that were either settled or terminated upon the closing of Histogenics&#146; initial public offering in the fourth quarter of 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses were $5.8 million in the third quarter of 2015, compared to $13.2 million in the third quarter of 2014. The decrease in
expense was primarily due to the expensing of license rights valued at $10.0 million and acquired as part of Histogenics&#146; exclusive channel collaboration with Intrexon Corporation in 2014 and was partially offset by higher costs related to the
NeoCart Phase 3 clinical trial and related development and manufacturing activities. General and administrative expenses were $2.2&nbsp;million in the third quarter of 2015, compared to $1.7 million in the third quarter of 2014. The increase was due
to various public company costs such as increased insurance premiums, board fees and stock compensation expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2015 Histogenics
had cash, cash equivalents and marketable securities of $37.7 million, compared to $58.1&nbsp;million at December&nbsp;31, 2014. Histogenics&#146; believes its current cash position will fund its operations into 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call and Webcast Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management will
host a conference call on Thursday, November&nbsp;12, 2015 at 8:30 a.m. EST. A question-and-answer session will follow Histogenics&#146; remarks. To participate on the live call, please dial (855)&nbsp;890-8663 (domestic) or (720)&nbsp;634-2936
(international) and provide the conference ID &#147;60793192&#148; five to ten minutes before the start of the call. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A live audio webcast of the
presentation will be available via the &#147;Investor Relations&#148; page of the Histogenics website, www.histogenics.com. A replay of the webcast will be archived on Histogenics&#146; website for approximately 30 days following the presentation.
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g28858ex99_1logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace.
Histogenics&#146; regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat
musculoskeletal-related conditions. Histogenics&#146; first investigational product candidate, NeoCart, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various statements in this
release, including, but not limited to, the guidance provided above, are &#147;forward-looking statements&#148; under the securities laws. Words such as, but not limited to, &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148;
&#147;could,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;design,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;target,&#148; &#147;likely,&#148; &#147;should,&#148; &#147;will,&#148; and &#147;would,&#148; or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon
current expectations that involve risks, changes in circumstances, assumptions and uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Important factors that could cause actual results to
differ materially from those reflected in the Company&#146;s forward-looking statements include, among others: the timing and success of Histogenics&#146; NeoCart Phase 3 clinical trial, including, without limitation, possible delays in enrolling
the NeoCart Phase 3 clinical trial; the ability to obtain and maintain regulatory approval of NeoCart or any product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing
Histogenics&#146; product candidates; the ability to obtain and maintain regulatory approval regarding the comparability of critical NeoCart raw materials following our technology transfer and manufacturing location transition; the size and growth
of the potential markets for Histogenics&#146; product candidates and the ability to serve those markets; Histogenics&#146; expectations regarding its expenses and revenue; the sufficiency of Histogenics&#146; cash resources and needs for additional
financing; Histogenics&#146; ability to attract or retain key personnel; the technologies on which Histogenics&#146; channel partnering agreement with Intrexon Corporation is based are currently in preclinical and clinical stages of development;
Histogenics will incur additional expenses in connection with its exclusive channel collaboration agreement with Intrexon Corporation and other factors that are described in the &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; sections of Histogenics&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2014 and Quarterly Report on Form 10-Q for the quarter ended June&nbsp;30, 2015, which are
on file with the SEC and available on the SEC&#146;s website at www.sec.gov. Additional factors may also be set forth in those sections of Histogenics&#146; Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2015, to be filed
with the SEC in the fourth quarter of 2015. In addition to the risks described above and in Histogenics&#146; annual report on Form 10-K and quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or
unpredictable factors also could affect Histogenics&#146; results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the actual results or developments anticipated by
Histogenics will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Histogenics. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and
estimates will be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All written and verbal forward-looking statements attributable to Histogenics or any person acting on its behalf are
expressly qualified in their entirety by the cautionary statements contained or referred to herein. Histogenics cautions investors not to rely too heavily on the forward-looking statements Histogenics makes or that are made on its behalf. The
information in this release is provided only as of the date of this release, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g28858ex99_1logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Histogenics undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future
events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g28858ex99_1logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HISTOGENICS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability, other liability and net sales distribution payment liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss attributable to common stockholders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per common share - basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute earnings per common share - basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,238,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,218,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g28858ex99_1logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HISTOGENICS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholder&#146;s equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor
Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +1 (781)&nbsp;547-7909 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">InvestorRelations@histogenics.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOURCE: Histogenics
Corporation </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g28858ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g28858ex99_1logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ - #8 P$1  (1 0,1 ?_$ +    $$ @,!
M       &!P@)!0H" P0! 0 !! ,! 0              !08'" (#! $)$
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MX_LUKYIH\2LK3S5BN)8WH:<,D%95O,IF4@ 1/O#S<S+0TM6=L-^W70+RGBW
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MF"+*MY]\4K9H^D&<,\6<,VAP3;@)Q$A-D_I=_ M529'>;SDM8BD5E#DBAM8
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M4 .\]#^,/$5(2;]O;\-BAML !L  '3Y  ;:0_4"9=/Q)\23#A0C;($S2-)2
M '@ !",R)CRL93I5EQY=H\9:HV^,6A[!&$>/&!GL<X[?.V!VQ60=H%5 @ (I
MG*;;?KUUVV^NJK75MW"C(37-J"DJTT(Z'4>$<-QM5%=J%VV5Z2NB=$E)[I/4
M0G\/83QM@:G(4'%=685.K(.W4@,>T5=.5',@^,4SM\^>OEG#QZ[6["@*BAS&
M[2E*&P  :ZKY?[UDU8;A?'?=JR -W8 S  D !_B83L:Q6R8C0)MU@9#%,%%1
M \2?]T(O*7$_ V:KW5,D9/H3.V6RDMT&E=?/9"61;-&[61&6:IKQK-ZW8/@;
MR0^4GF(?8W\.FE.SYIDV/V]^V6>I4S1U!)6D >J8VG4@GIVA-O\ Q]BF47.G
MN]^I14U]-_VU$D;9'<)!)$]>\>K+7%S"&=+13;AE:CL[E-T'R?I8\A(2J3%A
MY7K614\L8U=HQ[X#O&21Q!=-0!\8 /3IK58\OR3'*6HH+14J:I*J7N !,R )
M=9$Z>$B(Z+_@^,9-6TUQO5*E^MI0?:4HGT3,] #(Z]X36?.&/'KDR[B9/+]%
M2G9J#CQBHN=CI64@)AO%F547^VG>1#EH+MB1PJ*A$E@.0AS")0#<=^_%L_RO
M#%+_ &_5*:;<7N6D@*23_I(/X2A,R_C'#LYV?N.F#RVT;4*!V*2/]291YL%\
M)>-G'"15G<48UC8JR+(J-OU-+OI*QS[=LL @X;1\E-N7JT6BXW$#@V\7> B
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C "?S;NL]W\(DWIIP]8-$$&B"#1!!H@@T00:((-$$&B"/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
